Press Releases

pSivida Added to Russell Microcap Index WATERTOWN, Mass., Aug 04, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, announced that it has been added to the Russell

pSivida Announces Submission of Marketing Authorization Application for an Ophthalmic Product for Diabetic Macular Edema In Certain European Union Countries WATERTOWN, Mass., Jul 08, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back

pSivida Announces Submission of NDA to FDA for an Ophthalmic Product for Diabetic Macular Edema WATERTOWN, Mass., Jun 29, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat

pSivida CEO to Speak at Glaucoma & Retinopathies 2010 Conference in London WATERTOWN, Mass., Jun 15, 2010 (BUSINESS WIRE) --pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced

- $15.2m received from Alimera in full payment of conditional note after end of quarter.

pSivida Corp Announces Third Quarter 2010 Financial Results Release Date and Conference Call Information WATERTOWN, Mass., May 05, 2010 (BUSINESS WIRE) --pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of back of the eye drug delivery systems, today announced that its

Nine Presentations at ARVO to Feature pSivida Technologies

pSivida Receives $15 million payment from Alimera Sciences WATERTOWN, Mass., Apr 28, 2010 (BUSINESS WIRE) --pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note,

Newly-Published Peer-Reviewed Paper shows Durasert device was neuroprotectant in Retinitis Pigmentosa Model WATERTOWN, Mass., Apr 07, 2010 (BUSINESS WIRE) --pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ophthalmic sustained release drug delivery products, today said that a

Newly-Published Peer-Reviewed Paper shows Durasert device was neuroprotectant in Retinitis Pigmentosa Model WATERTOWN, Mass., Apr 07, 2010 (BUSINESS WIRE) --pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ophthalmic sustained release drug delivery products, today said that a

pSivida to Present at Cowen and Company Health Care Conference pSivida to Present at Cowen and Company Health Care Conference BOSTON, Mar 05, 2010 (BUSINESS WIRE) -- pSivida Corp, (NASDAQ:PSDV, ASX:PSD, FF:PV33), a leader in the development of ophthalmic sustained release drug delivery products,

pSivida Reports Presentation of Additional Positive 24-Month Data from Iluvien(R) Phase 3 FAME(TM) Study for Diabetic Macular Edema at Angiogenesis 2010 WATERTOWN, Mass., Mar 03, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA) (FF:PV3), a leader in the development of ophthalmic

pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2009 WATERTOWN, Mass., Feb 11, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) (FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for

pSivida Corp Announces Second Quarter 2010 Financial Results Release Date and Conference Call Information WATERTOWN, Mass., Feb 04, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA) (FF:PV3), a leading drug delivery company, today announced that its financial results for the second

pSivida CEO To Discuss Ocular Drug Delivery in Diabetic Retinopathy At 6th Annual Diabetes Conference January 22 in London WATERTOWN, Mass., Jan 20, 2010 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of tiny, sustained-release drug delivery

More patients receiving either the High Dose or Low Dose Iluvien showed improvement in best corrected visual acuity of 15 or more letters at 2 years compared to those receiving sham treatment. This was statistically significant.pSivida's licensee, Alimera Sciences, plans to file New Drug Application (NDA) in the second quarter of 2010.

pSivida Corp. Reports Results for the First Quarter Ended September 30, 2009 WATERTOWN, Mass. --(BUSINESS WIRE)--Nov. 12, 2009-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for

pSivida Corp. Announces First Quarter 2010 Financial Results Release Date and Conference Call Information WATERTOWN, Mass. --(BUSINESS WIRE)--Nov. 5, 2009-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FWB:PV3), a leading drug delivery company, today announced that its financial results for the first

pSivida Announces Completion of BrachySil(TM) Dose Ranging Study in Pancreatic Cancer WATERTOWN, Mass., Oct 21, 2009 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leading drug delivery company today announced the completion of a second pancreatic clinical trial of BrachySil

Top Line 24-Month Results Expected Mid-December from Pivotal Phase III Trial for Potential First Drug Treatment for Diabetic Macular Edema